Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
Open Access
- 20 December 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (1), e000493
- https://doi.org/10.1136/jitc-2019-000493
Abstract
Background Anti(α)-programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy fails to provide durable clinical benefit for most patients with carcinoma. Recent studies suggested that strategies to reduce immunosuppressive cells, promote systemic T-cell responses and lymphocyte trafficking to the tumor microenvironment (TME) may improve efficacy. N-809 is a first-in-class bifunctional agent comprising the interleukin (IL)-15 superagonist N-803 fused to two αPD-L1 domains. Thus, N-809 can potentially stimulate effector immune cells through IL-15 and block immunosuppressive PD-L1. Here, we examined the antitumor efficacy and immunomodulatory effects of N-809 versus N-803+αPD-L1 combination. Methods The ability of N-809 to block PD-L1 and induce IL-15-dependent immune effects was examined in vitro and in vivo. Antitumor efficacy of N-809 or N-803+αPD-L1 was evaluated in two murine carcinoma models and an extensive analysis of immune correlates was performed in the tumor and tumor-draining lymph node (dLN). Results We demonstrate that N-809 blocks PD-L1 and induces IL-15-dependent immune effects. N-809 was well-tolerated and reduced 4T1 lung metastasis, decreased MC38 tumor burden and increased survival versus N-803+αPD-L1. Compared with N-803+αPD-L1, N-809 enhanced natural killer (NK) and CD8+ T-cell activation and function in the dLN and TME, relating to increased gene expression associated with interferon and cytokine signaling, lymphoid compartment, costimulation and cytotoxicity. The higher number of TME CD8+ T cells was attributed to enhanced infiltration, not in situ expansion. Increased TME NK and CD8+ T-cell numbers correlated with augmented chemokine ligands and receptors. Moreover, in contrast to N-803+αPD-L1, N-809 reduced immunosuppressive regulatory T cells (Treg), monocytic myeloid-derived suppressor cells (M-MDSC) and M2-like macrophages in the TME. Conclusions Our results suggest that N-809 functions by a novel immune mechanism to promote antitumor efficacy. Foremost, N-809 enhances intratumoral lymphocyte numbers by increasing trafficking via altered chemokine levels in the TME and chemokine receptor expression on CD8+ T cells and NK cells. In addition, N-809 reduces immunosuppressive and pro-tumorigenic immune cells in the TME, including Treg, M2-like macrophages and M-MDSC. Overall, these novel effects of N-809 promote an inflamed TME, leading to lower tumor burden and increased survival. These results provide mechanistic insight and rationale supporting the potential clinical study of N-809 in patients with carcinoma.Keywords
Funding Information
- Intramural Research Program, National Cancer Institute, NIH (ZIA BC 010944: Strategies for Cancer Immunotherapy)
- Cooperative Research and Development Agreement between the National Cancer Institute and ImmunityBio, Inc. (CRADA #03063)
This publication has 50 references indexed in Scilit:
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With CancerJournal of Clinical Oncology, 2015
- Trafficking of T Cells into TumorsCancer Research, 2014
- Bispecific T‐cell engagers for cancer immunotherapyImmunology & Cell Biology, 2014
- Tumor targeting of the IL‐15 superagonist RLI by an anti‐GD2 antibody strongly enhances its antitumor potencyInternational Journal of Cancer, 2013
- Homeostatic maintenance of T cells and natural killer cellsCellular and Molecular Life Sciences, 2012
- The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomesProceedings of the National Academy of Sciences of the United States of America, 2010
- Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primatesBlood, 2010
- T-bet–dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrowThe Journal of Experimental Medicine, 2009
- FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptorsPharmacology & Therapeutics, 2005
- Mouse 4T1 Breast Tumor ModelCurrent Protocols in Immunology, 2000